How we score →

Hims Review

✓ Updated September 2026 By the TelehealthIndex Editorial Team · How we score Not Recommended · #8 in Men's Health (ED & TRT)
Advertising Disclosure: TelehealthIndex is reader-supported. If you sign up with a provider through links on this page, we may earn a commission at no extra cost to you. Commissions never influence our scores or rankings — several of our top-rated providers pay us nothing. How we score → · Full disclosure →
Caution: unresolved FDA warning letter. This provider stays at its computed rank; its score is capped under our methodology and it is not recommended while the matter is open.

Hims score

Not Recommended · #8 in Men's Health (ED & TRT) · Data as of September 2026
Clinical credibilityWeak
Regulatory & safety recordSerious deductions
Transparency & trustGood
Access & coverageMixed
Customer experienceGood
Value & pricingGood
Pillar ratings are qualitative summaries of our internal rubric; we do not publish the point weights. Read the full methodology →

TelehealthIndex scores and rankings are editorial opinions resulting from our selection, weighting, and interpretation of the factors described in our methodology.

What it is

Category revenue leader: erectile dysfunction (ED), hair, weight, testosterone replacement therapy (TRT); own 503A/503B pharmacies; mid-transition from compounded to brand glucagon-like peptide-1 (GLP-1) medications under Mar 2026 Novo deal.

Strengths

  • Available nationwide (50 states)
  • Lower-cost pricing for the category

Considerations

  • CONFIRMED FDA warning letter Sept 2025 (compounded semaglutide equivalency claims); no closeout letter found - Caution gate applies
  • Novo Nordisk terminated first partnership June 2025 citing deceptive marketing (renewed Mar 2026)
  • Securities class actions pending
  • FTC, California, and Utah sued Hims & Hers July 29, 2026, alleging deceptive privacy representations (sensitive health data shared with ad platforms) and obstructed subscription cancellation (FTC Act Section 5, ROSCA); action pending
  • Compounded chewable ED meds and enclomiphene are not FDA-approved
Note: this provider offers compounded medications for one or more services. Compounded medications are not FDA-approved.
Founded2017
OwnershipPublic (NYSE: HIMS)
AvailabilityNationwide (50 states)
InsuranceNo
Money-back guaranteeNot advertised
PricingED generics from $22/mo; hair from $22/mo; weight formerly $199/mo compounded, brand pricing in transition
Visit Hims We may earn a commission — disclosure.

Alternatives to consider

Marek Health Not Recommended · #7 in Men's Health (ED & TRT) — read review → BlueChew Not Recommended · #9 in Men's Health (ED & TRT) — read review →

Where Hims ranks

Weight Loss & GLP-1 Medications #10 of 11 — see the full ranking → Men's Health (ED & TRT) #8 of 10 — see the full ranking → Hair Loss & Dermatology #8 of 9 — see the full ranking → Online TRT Clinics #5 in this segment — see the full ranking → Online ED Treatment #5 in this segment — see the full ranking →

Compare Hims

Hims vs. Ro: our head-to-head Both cover ED, hair loss, and weight loss — we compare pricing, what's included, and how prescriptions work. Hims vs. Keeps: our head-to-head A platform that treats many conditions vs. a service that only does hair loss — price and treatment options compared.

Sources

Every regulatory claim on this page is cited to its primary source (or the issuing agency's database). Verified against the cited document; see our Editorial Policy.

Data as of September 7, 2026. Scores are editorial opinions reflecting documented business practices, transparency, pricing, access, and nonclinical consumer-service factors — not clinical quality or outcomes. Found an error? Report it →